3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Squamous Cell
3
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Large Cell
2
Breast Neoplasms
2
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Adenosquamous
1
Carcinoma
1
Advanced Cancer
1
Interventions
Carboplatin
7
Pemetrexed
5
pembrolizumab
4
Gemcitabine
4
osimertinib
3
Sorafenib
3
Paclitaxel
3
Interleukin-2
3
Cyclophosphamide
3
Cisplatin
3
seocalcitol
2
selinexor
2
patritumab
2
liposomal doxorubicin
2
interferon gamma-1b
2
fludarabine
2
Sunitinib
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Irinotecan
2
Erlotinib Hydrochloride
2
DNA
2
Celecoxib
2
Capecitabine
2
Bleomycin
2
Bevacizumab
2
Albumin-Bound Paclitaxel
2
130-nm albumin-bound paclitaxel
2
volociximab
1
thioredoxin reductase inhibitor AM12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma
×
figitumumab
×
Clear all
NCT00673049
2013-07-24
NSCLC
Pfizer
Phase 3
Terminated
583 enrolled
11 charts